The Omicron-adapted COVID-19 vaccine booster developed by Pfizer Inc. and BioNTech SE sharply reduced hospitalizations among older patients, Israeli researchers said on Monday, in some of the first evidence of the jab’s real-world effectiveness.
Tag Archive for: COVID-19 hospitalizations
No new coronavirus variant has been found in China, data released by the World Health Organization showed on Wednesday, easing some concerns about an outbreak that has spread rapidly there since Beijing abruptly reversed its “zero COVID” policy.
Leading scientists advising the World Health Organization said they wanted a “more realistic picture” about the COVID-19 situation from China’s top experts at a key meeting on Tuesday as worries grow about the rapid spread of the virus.
State media in China played down the severity of a surge of COVID-19 infections ahead of an expected briefing on Tuesday by its scientists to the World Health Organization, which is hoping for a “detailed discussion” on the evolution of the virus.
Merck & Co. Inc.’s COVID antiviral molnupiravir speeds up recovery but does not reduce the hospitalization or death rate in higher-risk vaccinated adults, detailed data from a large study showed on Thursday.
The risk of death, hospitalization and serious health issues from COVID-19 jumps significantly with reinfection compared with a first bout with the virus, regardless of vaccination status, a study published on Thursday suggests.
U.S. President Joe Biden said in an interview aired on Sunday that “the pandemic is over,” even though the country continues to grapple with coronavirus infections that kill hundreds of Americans daily.
In a recent large-scale study, Pfizer’s Paxlovid (nirmatrelvir and ritonavir tablets) appeared to be far more effective at reducing deaths and hospitalizations in older adults than younger patients stricken with the Omicron variant of COVID-19.
UnitedHealth Group Inc. on Friday raised its annual profit forecast for a second straight quarter, as a slow recovery in non-urgent medical procedures and lower COVID-care costs help it rein in medical expenses.
AstraZeneca announced Wednesday that the results of the company’s TACKLE Phase III trial of Evusheld (tixagevimab and cilgavimab, formerly AZD7442) for the early outpatient treatment of mild-to-moderate COVID-19 have been published in The Lancet Respiratory Medicine. Results of the trial showed that Evusheld protected against progression to severe COVID-19 or death – from any cause – compared to placebo.